SCHEDULE: Saturn V Capital Discloses 6.97% Stake in Immix Biopharma

Saturn V Capital Management LP and Xiaoying Tian have disclosed a 6.97% beneficial ownership stake in Immix Biopharma, Inc., totaling 3,693,585 shares.

Summary

• Saturn V Capital Management LP and Xiaoying Tian reported beneficial ownership of 3,693,585 shares of Immix Biopharma, Inc. common stock.
• This represents 6.97% of the company's outstanding common stock, based on 52,955,130 shares as of January 8, 2026.
• Saturn V Capital Management LP acts as the investment manager for certain pooled investment vehicles and managed accounts, holding these shares.
• Xiaoying Tian is the Managing Member of SVCM GP LLC, the general partner of Saturn V Capital Management LP.
• Both reporting persons possess shared voting and dispositive power over the shares but disclaim beneficial ownership of shares held by their clients.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it indicates an institutional investor's confidence in Immix Biopharma, though it provides no new operational or financial data.

Positives

• A significant institutional investor, Saturn V Capital Management LP, has taken a substantial stake in Immix Biopharma, indicating potential confidence in the company's prospects.

Industry Context

StockSavvy.ai notes that the disclosure of a significant institutional stake, such as this 6.97% position by Saturn V Capital Management, is a routine event in the public markets. While not providing specific operational or financial details, it signals an institutional investor's belief in Immix Biopharma's long-term potential, a common occurrence in the biopharma sector where long-term investment horizons are typical.

Comparison to Industry Standards

• StockSavvy.ai observes that a 6.97% stake is a notable position for an institutional investor, often placing them among the top shareholders. For comparison, similar disclosures by funds like ARK Invest or BlackRock in other biotech firms often involve stakes ranging from 5% to 15%, depending on the company's market capitalization and the fund's investment strategy.
• The filing adheres to standard SEC disclosure requirements for beneficial ownership exceeding 5%, consistent with practices across the U.S. public market.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a substantial shareholder may influence strategic decisions, though the filing states the stake is not for control purposes.

Key Dates

Recommendation

While the disclosure of a significant institutional stake by Saturn V Capital Management is a positive signal of investor confidence, this Schedule 13G filing alone does not provide sufficient operational or financial details to warrant a 'buy' or 'sell' recommendation. A seasoned investor would 'hold' and await further financial reports or strategic updates from Immix Biopharma to make a more informed decision, using this filing as an indicator of institutional interest.

Keywords

Immix Biopharma, Saturn V Capital Management, Xiaoying Tian, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biopharma